Climb Bio Inc
CLYM
Company Profile
Business description
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Contact
20 William Street
Suite 145
Wellesley HillsMA02481
USAT: +1 866 857-2596
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
29
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
stocks
Will Australia’s dwindling fuel supplies impact this share?
Australia’s petrol reserves have dropped from 60 to 35 days.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.20 | 4.30 | -0.05% |
| CAC 40 | 7,908.74 | 53.65 | -0.67% |
| DAX 40 | 22,921.59 | 246.49 | -1.06% |
| Dow JONES (US) | 46,552.72 | 117.16 | -0.25% |
| FTSE 100 | 10,348.79 | 87.50 | -0.84% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,977.19 | 19.15 | -0.09% |
| Nikkei 225 | 53,429.56 | 15.88 | 0.03% |
| NZX 50 Index | 13,069.66 | 167.51 | 1.30% |
| S&P 500 | 6,608.31 | 3.52 | -0.05% |
| S&P/ASX 200 | 8,728.80 | 1.50 | -0.02% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |